Prior IOI a potential risk factor for adverse events after brolucizumab treatment
Data presented at AAO 2020 Virtual identified baseline characteristics that may be linked with inflammation-related adverse events after treatment with brolucizumab (Beovu; Novartis).
Data from the IRIS Registry of 12,000 patients with wet age-related macular degeneration (AMD) treated with brolucizumab, were analyzed. Patients who had prior intraocular inflammation (IOI) and/or prior retinal vascular occlusion (RO) in the 12 months before their first injection with brolucizumab, were at the highest observed risk for experiencing retinal vasculitis (RV) and/or RO in the 6 months after treatment.
The observed overall risk rate of RV/RO was 0.46% for all patients treated with brolucizumab and 3.97% in patients with prior IOI and/or RO.
“Certain patient populations are driving the observed increase in the risk rate,” said Michael S Ip MD during the presentation. “It’s those patients that have prior interocular inflammation or retinal occlusion, whether male or female, that are driving this increase in the risk rate.”
In June 2020, the U.S. Food and Drug Administration approved a label updated for brolucizumab to include additional safety information regarding RV and RO.
Ip M, et al. The Brolucizumab Experience Thus Far: A Health Economics and Outcomes Research Analysis. Presented at: AAO 2020 Virtual. November 2020.